Cipla LtdNSE: CIPLA

Press Release Dec 28 2021

· Issued by Cipla Ltd

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Cipla plans to make Cipmolnu® available at pharmacies and COVID treatment centers across the country. The approval follows a collaborative trial and a licensing agreement with Merck Sharpe Dohme for manufacturing and supply.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Cipla Limited has informed the Exchange regarding a press release dated December 28, 2021, titled "Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu�� (Molnupiravir 200 mg) in India to treat mild to moderate COVID-19 at high risk of developing severe disease".

Cipla Ltd on 6ix

Earlier from Cipla

Later from Cipla

All Cipla news releases